Cargando…
LPA(1) antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a debilitating lung disease with limited treatment options. A phase 2 trial (NCT01766817) showed that twice-daily treatment with BMS-986020, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, significantly decreased the slope of forced vital ca...
Autores principales: | Decato, Benjamin E., Leeming, Diana Julie, Sand, Jannie Marie Bülow, Fischer, Aryeh, Du, Shuyan, Palmer, Scott M., Karsdal, Morten, Luo, Yi, Minnich, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933988/ https://www.ncbi.nlm.nih.gov/pubmed/35303880 http://dx.doi.org/10.1186/s12931-022-01980-4 |
Ejemplares similares
-
BMS-986020, a Specific LPA(1) Antagonist, Provides Neuroprotection against Ischemic Stroke in Mice
por: Gaire, Bhakta Prasad, et al.
Publicado: (2020) -
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
por: Corte, Tamera J, et al.
Publicado: (2021) -
Development of a Novel Enzyme-Linked Immunosorbent Assay Targeting a Neo-Epitope Generated by Cathepsin-Mediated Turnover of Type III Collagen and Its Application in Chronic Obstructive Pulmonary Disease
por: Rasmussen, Daniel Guldager Kring, et al.
Publicado: (2017) -
Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort
por: Rønnow, Sarah Rank, et al.
Publicado: (2019) -
Serum Type XIX Collagen is Significantly Elevated in Non-Small Cell Lung Cancer: A Preliminary Study on Biomarker Potential
por: Thorlacius-Ussing, Jeppe, et al.
Publicado: (2020)